AnaCardio
Series A in 2022
AnaCardio is a clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company’s therapeutic drugs aim to enhance the contractility of the heart muscle through a unique mechanism involving a therapeutic peptide. This approach is designed to avoid common adverse effects associated with heart treatments, such as tachycardia, arrhythmia, ischemia, and hypotension. By improving cardiac output safely, AnaCardio's therapies have the potential to enhance organ function, boost quality of life, increase functional capacity, and reduce the risk of hospitalization and mortality in patients with heart failure.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.